Pulmonary hypertension:

Indications for: VELETRI

Pulmonary arterial hypertension (PAH; WHO Group I) in patients with NYHA Class III or IV symptoms, to improve exercise ability.

Adult Dosage:

Give by continuous chronic IV infusion through a central venous catheter. Initially 2ng/kg/min; increase in increments of 1–2ng/kg/min at ≥15min intervals based on response. Decrease dose gradually in 2ng/kg/min decrements at ≥15min intervals until dose-limiting effects resolve.

Children Dosage:

Not established.

VELETRI Contraindications:

Heart failure due to severe left ventricular systolic dysfunction. Pulmonary edema.

VELETRI Warnings/Precautions:

Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Risk of pulmonary embolism or systemic embolism; give anticoagulant therapy unless contraindicated. Monitor BP and heart rate during initiation and after dose changes. Pregnancy. Nursing mothers.

VELETRI Classification:

Prostacyclin analogue.

VELETRI Interactions:

Hypotensive effects may be potentiated by diuretics, antihypertensive agents, other vasodilators. Increased risk of bleeding with anticoagulants, antiplatelets. May potentiate digoxin concentration; monitor for digoxin toxicity.

Adverse Reactions:

Nausea, vomiting, headache, hypotension, flushing, chest pain, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, tachycardia, jaw pain, diarrhea, flu-like symptoms, anxiety/nervousness.

Generic Drug Availability:


How Supplied:

Vial (10mL)—1